Prolonged Survival with Regorafenib in Metastatic Cholangiocarcinoma: Case Report
نویسندگان
چکیده
منابع مشابه
Extrahepatic cholangiocarcinoma with prolonged survival: a case report
BACKGROUND Cholangiocarcinoma has poor prognosis and short term-survival. Here, we report the case of a patient with unusually prolonged survival. CASE PRESENTATION Our patient was a 56-year-old Arab man with a 6-month history of obstructive jaundice. A computed tomography scan of his abdomen revealed a mass at the confluence of the hepatic ducts with suspected malignant strictures on endosco...
متن کاملEarly tumor cavitation with regorafenib in metastatic colorectal cancer: A case report
Tumoral cavity formation is a characteristic phenomenon reported in anti-angiogenic therapy in lung lesions. A 57-year-old male with multiple pulmonary metastases from colorectal cancer treated with an oral tyrosine kinase inhibitor, regorafenib, exhibited a characteristic cavity formation after the first two cycles. The decrease in the size of tumors was calculated as 38%, and there were assoc...
متن کاملDurable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report
Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer. Since this time, however, few case reports outlining real-world usage have been published in the literature. Here, we detail the clinical history of an elderly woman with KRAS wild-type colon cancer who received regora...
متن کاملMetastatic insulinoma – prolonged survival after multimodal approach
BACKGROUND Metastatic insulinoma is a disease associated with a poor life expectancy. CASE REPORT The case of a presently 68 year old female with malignant, metastatic insulinoma is reported. Due to severe clinical symptoms surgical tumor mass reduction was conducted. Furthermore the patient underwent a chemotherapy using streptozotocine and fluorouracil. After two years without any symptoms,...
متن کاملSorafenib Improves Survival in Metastatic Hepatocellular Carcinoma: A Case Report
Hepatocellular carcinoma (HCC) is a very common cancer. Curative treatments and local ones are well validated. Sorafenib, a multi-kinase receptor inhibitor was introduced in 2007 for advanced HCC in patients with preserved liver function. HCC is known to be resistant to systemic chemotherapy, and there are no validated therapies improving survival for metastatic disease. Herein, we report a cas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Advancements in Case Studies
سال: 2020
ISSN: 2639-0531
DOI: 10.31031/aics.2020.02.000542